Targeting Bcl-2 for the treatment of multiple myeloma

Abstract : Despite advances in the treatment of multiple myeloma, the disease still remains incurable for the majority of patients. The overexpression of anti-apoptotic proteins (i.e., Bcl-2, Bcl-X L or Mcl-1) is a hallmark of cancer and favors tumor cell survival and resistance to therapy. The oral drug venetoclax is the first-in-class Bcl-2-specific BH3 mimetic. In myeloma, in vitro sensitivity to venetoclax is mainly observed in plasma cells harboring the t(11;14) translocation, a molecular subgroup associated with high Bcl-2 and low Mcl-1/Bcl-XL expression. In addition with Bcl-2 members expression profile, functional tests as BH3 profiling or in vitro BH3 mimetic drug testing also predict sensitivity to the drug. Phase 1 clinical trials recently confirmed the efficacy of venetoclax monotherapy in heavily pretreated myeloma patients, mostly in patients with t(11;14). In combination with the proteasome inhibitor bortezomib, venetoclax therapy was found to be feasible and allowed promising response rate in relapsed myeloma patients, independent of t(11;14) status. The present review summarizes the current knowledge, "from bench to bedside", about venetoclax for the treatment of multiple myeloma.
Document type :
Journal articles
Complete list of metadatas

Cited literature [56 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01885190
Contributor : Elizabeth Bernardo <>
Submitted on : Monday, October 1, 2018 - 4:31:09 PM
Last modification on : Monday, May 20, 2019 - 3:32:02 PM
Long-term archiving on : Wednesday, January 2, 2019 - 2:57:31 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Cyrille Touzeau, Paulo Maciag, Martine Amiot, Philippe Moreau. Targeting Bcl-2 for the treatment of multiple myeloma. Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2018, 32 (9), pp.1899 - 1907. ⟨10.1038/s41375-018-0223-9⟩. ⟨inserm-01885190⟩

Share

Metrics

Record views

108